Clinical trials: Aromatase Inhibitor
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8
A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive Aromatase Inhibitor Therapy, AIMSS-RPS Trial
This phase II trial tests the safety and effectiveness of a dietary supplement called resistant potato starch for reducing musculoskeletal symptoms in patients with stage 0-III breast cancer or who are at high risk for breast…
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
- Trial name
- AIMSS-RPS (NCT07443943)
- Testing
- Starch, Potato
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Michigan Rogel Cancer Center
HER2-Positive Breast Carcinoma
Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk
This study assesses the effect of hormone directed treatment for breast cancer on glucose metabolism.
- Trial name
- NCT06557057
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Polymorphism, CYP19
Aromatase (CYP19) Polymorphism Between AI-responsive and AI-resistant Breast Cancer in Korea
Aromatase(CYP19)inhibitor is one of the major antihormonal drug for breast cancer in postmenopausal women. The variation of CYP19 may affect the effect of aromatase inhibitor.
- Conditions
- Polymorphism, CYP19, Aromatase Inhibitor
- Trial name
- CYP19 (NCT01137136)
- Where
- South Korea
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center
Breast Cancer Females
Short-term Impacts of Endocrine Therapy on Cardiovascular and Brain Health Outcomes in Breast Cancer
Aromatase inhibitors are the most used endocrine therapy for hormone-positive breast cancer. While there is a clear linear relationship between the duration of aromatase inhibitor use and the cumulative incidence of…
- Trial name
- STRIVE (Acute) (NCT06781762)
- Testing
- N/A (Usual Care)
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Periodontal Disease, Quality of Life
Oral Health in Breast Cancer Survivors on Aromatase Inhibitors
The purpose of this study is to determine how aromatase inhibitors (AIs) such as Arimidex, Aromasin or Femara affect a woman's oral health and oral health related quality of life.
- Trial name
- NCT01693731
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Breast Cancer Females
Chronic Impacts of Endocrine Therapy on Cardiovascular and Brain Health Outcomes in Breast Cancer
Aromatase inhibitors are the most used endocrine therapy for hormone-positive breast cancer. Despite the evidence that aromatase inhibitor therapy is associated with increased risk of cardiovascular events, potentially related to…
- Trial name
- STRIVE-Chronic (NCT06776458)
- Testing
- N/A - Usual Care
- Where
- Canada
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- University of Toronto